Mariana L Casalia1, MacKenzie A Howard1, Scott C Baraban1. 1. Epilepsy Research Laboratory, Department of Neurological Surgery and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA.
Abstract
OBJECTIVE: A significant proportion of the more than 50 million people worldwide currently suffering with epilepsy are resistant to antiepileptic drugs (AEDs). As an alternative to AEDs, novel therapies based on cell transplantation offer an opportunity for long-lasting modification of epileptic circuits. To develop such a treatment requires careful preclinical studies in a chronic epilepsy model featuring unprovoked seizures, hippocampal histopathology, and behavioral comorbidities. METHODS: Transplantation of progenitor cells from embryonic medial or caudal ganglionic eminence (MGE, CGE) were made in a well-characterized mouse model of status epilepticus-induced epilepsy (systemic pilocarpine). Behavioral testing (handling and open field), continuous video-electroencephalographic (vEEG) monitoring, and slice electrophysiology outcomes were obtained up to 270 days after transplantation (DAT). Post-hoc immunohistochemistry was used to confirm cell identity. RESULTS: MGE progenitors transplanted into the hippocampus of epileptic mice rescued handling and open field deficits starting at 60 DAT. In these same mice, an 84% to 88% reduction in seizure activity was observed between 180 and 210 DAT. Inhibitory postsynaptic current frequency, measured on pyramidal neurons in acute hippocampal slices at 270 DAT, was reduced in epileptic mice but restored to naïve levels in epileptic mice receiving MGE transplants. No reduction in seizure activity was observed in epileptic mice receiving intrahippocampal CGE progenitors. INTERPRETATION: Our findings demonstrate that transplanted MGE progenitors enhance functional GABA-mediated inhibition, reduce spontaneous seizure frequency, and rescue behavioral deficits in a chronic epileptic animal model more than 6 months after treatment. Ann Neurol 2017;82:530-542.
OBJECTIVE: A significant proportion of the more than 50 million people worldwide currently suffering with epilepsy are resistant to antiepileptic drugs (AEDs). As an alternative to AEDs, novel therapies based on cell transplantation offer an opportunity for long-lasting modification of epileptic circuits. To develop such a treatment requires careful preclinical studies in a chronic epilepsy model featuring unprovoked seizures, hippocampal histopathology, and behavioral comorbidities. METHODS: Transplantation of progenitor cells from embryonic medial or caudal ganglionic eminence (MGE, CGE) were made in a well-characterized mouse model of status epilepticus-induced epilepsy (systemic pilocarpine). Behavioral testing (handling and open field), continuous video-electroencephalographic (vEEG) monitoring, and slice electrophysiology outcomes were obtained up to 270 days after transplantation (DAT). Post-hoc immunohistochemistry was used to confirm cell identity. RESULTS:MGE progenitors transplanted into the hippocampus of epilepticmice rescued handling and open field deficits starting at 60 DAT. In these same mice, an 84% to 88% reduction in seizure activity was observed between 180 and 210 DAT. Inhibitory postsynaptic current frequency, measured on pyramidal neurons in acute hippocampal slices at 270 DAT, was reduced in epilepticmice but restored to naïve levels in epilepticmice receiving MGE transplants. No reduction in seizure activity was observed in epilepticmice receiving intrahippocampal CGE progenitors. INTERPRETATION: Our findings demonstrate that transplanted MGE progenitors enhance functional GABA-mediated inhibition, reduce spontaneous seizure frequency, and rescue behavioral deficits in a chronic epileptic animal model more than 6 months after treatment. Ann Neurol 2017;82:530-542.
Authors: Katharine W Henderson; Jyoti Gupta; Stephanie Tagliatela; Elizabeth Litvina; XiaoTing Zheng; Meghan A Van Zandt; Nicholas Woods; Ethan Grund; Diana Lin; Sara Royston; Yuchio Yanagawa; Gloster B Aaron; Janice R Naegele Journal: J Neurosci Date: 2014-10-01 Impact factor: 6.167
Authors: Derek G Southwell; Cory R Nicholas; Allan I Basbaum; Michael P Stryker; Arnold R Kriegstein; John L Rubenstein; Arturo Alvarez-Buylla Journal: Science Date: 2014-04-11 Impact factor: 47.728
Authors: Derek G Southwell; Mercedes F Paredes; Rui P Galvao; Daniel L Jones; Robert C Froemke; Joy Y Sebe; Clara Alfaro-Cervello; Yunshuo Tang; Jose M Garcia-Verdugo; John L Rubenstein; Scott C Baraban; Arturo Alvarez-Buylla Journal: Nature Date: 2012-10-07 Impact factor: 49.962
Authors: Collin B Merrill; Lindsey N Friend; Scott T Newton; Zachary H Hopkins; Jeffrey G Edwards Journal: Sci Rep Date: 2015-11-10 Impact factor: 4.379
Authors: Mariana L Casalia; Tina Li; Harrison Ramsay; Pablo J Ross; Mercedes F Paredes; Scott C Baraban Journal: J Neurosci Date: 2021-02-26 Impact factor: 6.167
Authors: Eung Chang Kim; Jiaren Zhang; Andy Y Tang; Eric C Bolton; Justin S Rhodes; Catherine A Christian-Hinman; Hee Jung Chung Journal: Proc Natl Acad Sci U S A Date: 2021-12-21 Impact factor: 12.779
Authors: Magdalena Martinez-Losa; Tara E Tracy; Keran Ma; Laure Verret; Alexandra Clemente-Perez; Abdullah S Khan; Inma Cobos; Kaitlyn Ho; Li Gan; Lennart Mucke; Manuel Alvarez-Dolado; Jorge J Palop Journal: Neuron Date: 2018-03-15 Impact factor: 17.173
Authors: Dina L Juarez-Salinas; Joao M Braz; Alexander Etlin; Steven Gee; Vikaas Sohal; Allan I Basbaum Journal: Brain Date: 2019-09-01 Impact factor: 13.501